FX.co ★ Tempest Inks Deal With Roche To Support Advancement Of Amezalpat Combination Therapy

Tempest Therapeutics, Inc. (TPST), a biotechnology firm, has announced a partnership with the Roche Group (RHHBY.PK) to progress the study of amezalpat (TPST-1120). This study will involve a combination with atezolizumab (Tecentriq) and bevacizumab, which are currently the standard treatments for unresectable or metastatic hepatocellular carcinoma (HCC). The aim is to move into a critical Phase 3 trial focused on the first-line treatment for this difficult-to-treat form of liver cancer with significant unmet needs.

According to the agreement, Roche will globally supply atezolizumab, while Tempest will both sponsor and lead the pivotal study. Tempest is targeting the beginning of the Phase 3 study in the first quarter of 2025.

This agreement is an extension of an existing clinical collaboration between the two companies, in which amezalpat was combined with atezolizumab and bevacizumab for first-line HCC patients and its efficacy was compared to just atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest maintains all development and commercial rights for amezalpat.